- Home
- WYY vs NRXP Comparison
WYY vs NRXP Comparison
Compare WYY & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- NRXP
- Stock Information
- Founded
- WYY 1991
- NRXP 2015
- Country
- WYY United States
- NRXP United States
- Employees
- WYY N/A
- NRXP N/A
- Industry
- WYY EDP Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- WYY Technology
- NRXP Health Care
- Exchange
- WYY Nasdaq
- NRXP Nasdaq
- Market Cap
- WYY 33.6M
- NRXP 32.6M
- IPO Year
- WYY 1998
- NRXP N/A
- Fundamental
- Price
- WYY $3.26
- NRXP $3.37
- Analyst Decision
- WYY Strong Buy
- NRXP Strong Buy
- Analyst Count
- WYY 1
- NRXP 4
- Target Price
- WYY $7.00
- NRXP $28.50
- AVG Volume (30 Days)
- WYY 79.9K
- NRXP 284.1K
- Earning Date
- WYY 08-13-2025
- NRXP 08-13-2025
- Dividend Yield
- WYY N/A
- NRXP N/A
- EPS Growth
- WYY N/A
- NRXP N/A
- EPS
- WYY N/A
- NRXP N/A
- Revenue
- WYY $142,582,209.00
- NRXP N/A
- Revenue This Year
- WYY $10.84
- NRXP N/A
- Revenue Next Year
- WYY $12.37
- NRXP N/A
- P/E Ratio
- WYY N/A
- NRXP N/A
- Revenue Growth
- WYY 24.03
- NRXP N/A
- 52 Week Low
- WYY $2.19
- NRXP $1.10
- 52 Week High
- WYY $6.25
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- WYY 45.19
- NRXP 58.22
- Support Level
- WYY $3.21
- NRXP $2.90
- Resistance Level
- WYY $3.46
- NRXP $3.53
- Average True Range (ATR)
- WYY 0.20
- NRXP 0.21
- MACD
- WYY 0.04
- NRXP -0.04
- Stochastic Oscillator
- WYY 44.64
- NRXP 66.20
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.